Immune cell containing tumor antigen recognition receptor and application of immune cell

A technology of immune cells and tumor antigens, applied in receptors/cell surface antigens/cell surface determinants, medical preparations containing active ingredients, applications, etc. Difficulty secreting T cells

Pending Publication Date: 2019-06-21
SUZHOU KANGJU BIOTECHNOLOGY CO LTD
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The technical problem to be solved by the present invention is to overcome the inability to obtain CAR-T cells with hyaluronic acid degradation activity in the current prior art, and at the same time, the positive rate of CAR is also very low or the CAR-T cells containing hyaluronidase are difficult to secrete Hyaluronidase, thus unable to obtain effective deficiencies in immune cells containing tumor antigen recognition receptors, providing an immune cell containing tumor antigen recognition receptors and application thereof

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune cell containing tumor antigen recognition receptor and application of immune cell
  • Immune cell containing tumor antigen recognition receptor and application of immune cell
  • Immune cell containing tumor antigen recognition receptor and application of immune cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1. Design of CAR / TCR sequence

[0051] The proteins involved in the present invention include PH20, CD8α hinge region, human CD8α transmembrane region, human 4-1BB intracellular region and human CD3ζ intracellular region, MSLN, HAS2 (hyaluronidase synthesis gene) and targeting each Target scFv sequence, TCR sequence. The NCBI accession number of PH20 amino acid sequence is NP_694859.1 (cDNA is NM_153189.2); the NCBI accession number of HAS2 is NP_005319.1 (cDNA is NM_005328.3); the NCBI accession number of MSLN is NP_037536.2 (cDNA is NM_013404 .4); tEGFR is the III and IV domains of EGFR, and the NCBI accession number of EGFR is NP_005219.2 (cDNA is NM_005228.4). The amino acid sequence and coding base sequence of MSLN scFv (SS1) are derived from patent US7977457 (SEQ ID NO 12); the amino acid sequence of GPC3 scFv is derived from patent CN104140974A (SEQ ID NO 22), and the base sequence is obtained by codon optimization for human ; The amino acid sequence an...

Embodiment 2

[0066] Example 2. Vector Construction

[0067] The base sequences of PH20 and CAR / TCR synthesized in Example 1 were digested with EcoRI and XbaI, connected with DNALigation Kit (Takara) and inserted into the corresponding sites of the lentiviral vector pCDH-EF1a (SBI) ( figure 1 ), to obtain the target gene expression vector Lenti-GOI. The base sequence of MSLN was digested with BamHI and EcoRI, and inserted into the corresponding site of pcDNA3.1 vector (Invitrogen) by DNA Ligation Kit (Takara); the base sequence of HAS2 was digested by NheI and BamHI, and inserted into pcDNA3 by DNA Ligation Kit. . Corresponding sites of 1-Hyg vector (Invitrogen). The ligation products were transformed into competent Escherichia coli (Top10). On the second day after transformation, the clones were picked and cultured in LB liquid medium containing 100 μg / mL ampicillin (Saigon Biotechnology), and sequenced for identification. The clones with correct sequencing results were selected and ino...

Embodiment 3

[0070] Example 3. Lentiviral packaging

[0071] Prepare a 10cm cell culture dish and inoculate 5×10 6 293 cells / dish, add complete medium DMEM high glucose (GIBCO) + 10% FBS (GIBCO), place at 37°C, 5% CO 2 incubator, overnight.

[0072] Take out 1 mg / ml polyetherimide (PEI, Polyscience) transfection reagent and lentiviral packaging plasmid (Lenti-GOI, pMD2.G, psPAX2), and thaw at room temperature. Remove the HBSS buffer and warm to room temperature. Take 2 mL of PBS to one well of a 6-well plate, add 10 μg Lenti-GOI, 7 μg psPAX2, 4 μg pMD2.G and mix well, add 63 μL PEI transfection reagent and mix well with a pipette, and let stand at room temperature for 10 minutes. Add the DNA / PEI complex drop by drop to a 10cm Petri dish, shake the Petri dish gently, and mix well. Place the Petri dish at 37°C, 5% CO 2 Incubator, after culturing for 6-8 hours, remove the medium containing the transfection reagent, replace it with fresh complete medium and put it back into the incubator ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an immune cell containing a tumor antigen recognition receptor and application of the immune cell. The immune cell containing the tumor antigen recognition receptor expresses hyaluronidase, wherein the hyaluronidase comprises: a) a full-length protein anchored to the immune cell; or b) a soluble protein secreted to the outside of the immune cell. The invention also discloses application of the immune cell in preparation of drugs for treating tumors. According to the immune cell containing the tumor antigen recognition receptor, an effect of normalizing a tumor immune microenvironment by changing the extracellular matrix structure of the microenvironment can be changed, so that the immune cell can effectively approach and kill tumor cells. With the help of the soluble PH20 protein, the immune cell containing the tumor antigen recognition receptor can also improve the tumor microenvironment and effectively kill the tumor cells.

Description

technical field [0001] The invention belongs to the field of cell immunotherapy, and in particular relates to an immune cell containing a tumor antigen recognition receptor and an application thereof. Background technique [0002] Cancer, also known as malignant tumor, is the most serious disease and persistent disease that seriously endangers human health and causes death of modern humans. According to statistics from the United Nations, one out of every eight deaths in the world is currently caused by cancer, which is higher than the number of deaths caused by AIDS, tuberculosis and malaria. Moreover, more than 10 million people around the world are diagnosed with cancer every year ("World Cancer Report 2014" released by the World Health Organization). [0003] Traditionally, cancer treatment has been based on surgery, chemotherapy, and radiotherapy. However, traditional treatment methods can only prolong the survival period of patients with malignant tumors, and the pos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/10C12N15/867A61K35/17A61P35/00
CPCC12N5/0636C12N9/2474C12Y302/01035C07K16/30C07K14/7051A61K39/001154A61P35/00C12N2510/00C12N2740/15043C07K2319/03C07K2319/74A61K2039/5158C12N15/867C12N5/10A61K39/4632A61K39/464411A61K39/4631A61K39/464468A61K39/4611A61K39/464454A61K39/4613A61K2239/38A61K2239/31A61K2239/54A61K39/464466
Inventor 王征徐云霞
Owner SUZHOU KANGJU BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products